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Abstract	
This	dissertation	was	written	as	part	of	the	MA	in	Art,	Law	and	Economy	at	the	Inter-
national	Hellenic	University.		
In	 this	dissertation,	 there	will	be	an	analysis	of	pharmaceutical	patents	and	 some	 is-
sues	that	are	created	due	to	their	existence.	In	the	first	chapter,	there	will	be	an	analy-
sis	of	what	is	medicine,	which	are	its	types	and	especially	an	analysis	of	generics,	since	
they	play	a	major	role	in	in	the	pharmaceutical	industry.		
In	the	second	chapter,	there	will	be	an	analysis	of	the	types	of	pharmaceutical	patents	
and	 the	 special	 certificate	 for	pharmaceuticals,	 the	 supplementary	protection	 certifi-
cate.	Moreover,	the	economical	and	technological	use	of	pharmaceutical	patents	will	
also	 be	 discussed.	 The	 interaction	 of	 archetypes	 and	 generics	 in	 the	 pharmaceutical	
industry	affects	this	 industry	through	aspects	such	as	competition,	parallel	 import,	 li-
censes	and	access	 to	medicines,	 issues	 that	will	be	discussed	 in	 the	 third	and	 fourth	
chapter.	Some	case	study	will	be	provided	concerning	not	only	these	 issues,	but	also	
other	great	issues,	such	as	the	AstraZeneca	case,	that	have	affected	the	pharmaceuti-
cal	industry.	Finally,	some	conclusions	that	were	made	after	this	research	will	be	pro-
vided	in	the	last	chapter.	
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Introduction	
Intellectual	 Property	 Law	 is	 the	 area	 of	 law	 that	 concerns	 legal	 rights	 that	 associate	
with	 creative	 effort	 or	 commercial	 reputation.1	 There	 are	many	 reasons	 behind	 the	
existence	of	Intellectual	Property.	Some	of	them	are	the	encouragement	of	innovation,	
cultural	 development	 and	 the	 development	 of	 global	 commercial	 transactions	 and	
marketing.2		
Patent	Law	is	one	kind	of	Intellectual	Property	Rights	and	it	concerns	new,	industrially	
applicable	inventions.3	It	can	be	defined	as	the	grant	by	a	state	of	exclusive	rights	for	a	
limited	time	as	“reward”	for	the	new	and	useful	invention.4	A	pharmaceutical	patent	is	
granted	for	an	 initial	discovery.5	 It	gives	 the	pharmaceutical	company	a	monopoly	 to	
work,	promote	and	sell	the	medicine	by	excluding	all	the	others	from	it.	This	monopoly	
is	not	an	absolute	one,	since	there	are	some	checks	and	balances.	Patents	are	the	most	
effective	choice	to	protect	an	invention	and	its	investment.6		
Patents	exist	only	as	provided	in	the	national	law	of	every	state,	and	can	be	enforced	
only	to	the	extent	that	application	has	been	made	and	a	patent	granted	covering	the	
territory	of	an	individual	state.7	Thus,	they	are	concerned	to	generally	be	limited	to	the	
territory	of	the	state	that	has	granted	it.	Since	someone	wishes	to	expand	the	right	to	
																																																						
1	(Bainbridge,	2007),	p.	3.	
2	(Μαρίνος,	2013),	p.	1.	
3	(Bainbridge,	2007),	p.343.		
4	(Grubb,	1999),	p.	3.	
5	(Priddis	and	Constantine,	2011),	p.	256.	
6	(Bainbridge,	2007),	p.	343-344.	
7	(Lehamn,	2003),	p.2. 
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more	states,	then	a	separate	license	must	be	granted	in	all	of	them.8	Currently,	inven-
tions	can	be	protected	 in	European	Union	either	by	national	patents,	granted	by	the	
competent	national	 Intellectual	Property	authorities	 in	E.U.	countries	or	by	European	
patents	granted	centrally	by	the	European	Patent	Office	(EPO).9	It	came	into	effect	in	
1977	 and	 applicants	 could	 then	 file	 a	 single	 patent	 application	with	 the	 EPO	 that,	 if	
granted,	was	applicable	in	all	the	member	–	States	that	the	claimant	chose.10	Inventors	
can	also	file	a	claim	to	the	World	Intellectual	Property	Organization	(WIPO)	in	order	to	
request	 the	grant	of	national	patents	 in	any	 country	 that	 is	 a	member	 in	 the	Patent	
Cooperation	 Treaty	 (PCT).	 This	 method	 is	 quicker	 and	 can	 provide	 multiple	 patents	
granted	 in	different	countries	with	only	one	application.11	After	the	expiry	of	 the	pa-
tent,	the	invention	falls	into	the	public	domain,	where	everyone	can	use	it.	
Pharmaceutical	patents	play	a	 crucial	 role	 for	 the	existence	and	 the	development	of	
pharmaceutical	industry.	In	this	dissertation,	the	reasons	that	pharmaceutical	patents	
are	so	 important	will	be	analyzed,	by	examining	the	hidden	roles	that	they	have	and	
how	they	interact	with	competition,	the	market	and	healthcare	at	the	same	time.	The	
discussion	about	patent	law	and	pharmaceutical	industry	is	immense.		
First	of	all,	medicines	will	be	defined	 in	order	to	understand,	why	pharmaceutical	 in-
dustry	is	complicated	and	how	one	type	of	medicines,	the	generics,	influences	the	bal-
ance	of	 it.	The	clash	between	prototypes	and	generics	need	some	analysis	 to	under-
stand	deeper	the	problems	that	occur	in	the	pharmaceutical	industry.	Moreover,	since	
pharmaceutical	patents	are	more	complicated	than	the	other	patents,	it	is	vital	to	de-
fine	the	different	 types	of	pharmaceutical	patents,	which	are	the	main	tools	used	by	
pharmaceutical	companies	to	protect	their	 innovative	 inventions.	 In	pharmaceuticals,	
there	 is	also	a	different	 type	of	 intellectual	property	 right	 that	enhances	 this	protec-
																																																						
8	(Grubb,	1999),	p.	3.	
9	(European	Commission,	2017).		
10	(Λεφάκης,	2004),	p.	121.	
11	(WIPO,	2015).		
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tion,	 the	SPC.	Of	 course,	 it	 is	 important	 to	explain	why	pharmaceutical	patents	have	
both	an	economical	and	technological	use.	
The	commercial	exploitation	of	pharmaceutical	patents	is	a	huge	issue	that	needs	a	lot	
of	analysis.	Pharmaceutical	market	works	differently	compared	to	other	markets,	since	
demand	and	offer	are	affected	by	different	and	more	complicated	factors.	Competition	
law	 in	 the	E.U.	 interacts	with	pharmaceutical	patents,	 since	 their	existence	seems	 to	
promote	 fair	 competition	 and	 innovation.	 However,	 wherever	 balance	 is	 offended,	
problems	rise	and	strike	competitions	well-being.	Access	to	medicines	seems	to	be	the	
main	problem	of	both	developed	and	developing	countries,	since	the	absolute	protec-
tion	of	medicines	creates	also	problems	to	pharmaceuticals’	accessibility.	These	issues	
will	be	examined	in	this	dissertation	to	understand	better	and	deeper	pharmaceutical	
patents	and	how	they	interact	with	pharmaceutical	industry.	
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WHAT	IS	A	MEDICINE?	
Since	pharmaceutical	patents	are	to	be	analyzed,	it	is	essential	to	first	give	a	definition	
concerning	“medicines”.	Medicine	 is	 a	product	 that	has	 special	physical	 capacity	and	
consists	 various	 ingredients	 in	 specific	 quantities	 that	 follow	 a	 specific	 procedure.	 A	
medicine	 is	 considered	 to	 become	 a	 pharmaceutical	 product	 from	 the	moment	 it	 is	
produced	in	a	massive	quantity.12	When	a	medicine	is	first	developed	by	a	pharmaceu-
tical	company,	it	is	sold	under	this	company’s	brand	name	and	it	is	protected	by	patent	
law13,	 provided	 a	 request	 for	 it	 was	 filed	 and	 granted	 by	 the	 procedure	mentioned	
above.	According	to	the	Cambridge	Dictionary,	“medicine	is	a	substance	that	cures	an	
illness	or	an	injury”.14		
	TYPES	OF	MEDICINES	
Generally,	four	types	of	medicines	can	be	found	in	the	pharmaceutical	industry:		
i. Ethical	medicines	(which	can	be	prescribed	by	a	medical	practitioner),	
ii. Over	–	The	–	Counter	(O.T.C.)		medicines	(which	are	not	prescribed	by	a	medical	
practitioner),	
iii. Generic	medicines	(analyzed	below),	
iv. Biotech	medicines.15	
																																																						
12	(Καφετζής,	2013),	p.	16.	
13	(Mandal,	2014).		
14	(Cambridge	Dictionary,	n.d.).	
15	(Φαρμάκης,	2012),	p.	14.	
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After	the	implementation	of	paragraph	6	of	the	Doha	Declaration	on	the	TRIPs	Agree-
ment	and	public	health	in	2003,	a	new	definition	concerning	medicines	started	to	exist.	
According	 to	 it,	 “pharmaceutical	 product”	means	 “any	 patented	 product,	 or	 product	
manufactured	through	a	patented	process,	of	the	pharmaceutical	sector	needed	to	ad-
dress	the	public	health	problems.	It	is	understood	that	active	ingredients	necessary	for	
its	manufacture	and	diagnostic	kits	needed	for	its	use	would	be	included.”.16		
As	 far	 as	 the	 E.U.	 is	 concerned,	 the	Directive	 2001/83/EC	 provides	 rules	 relating	 to	
medical	products	for	human	use.	Article	1	(1)	refers	to	“proprietary	medical	product”	
as	“any	ready	–	prepared	medical	product	placed	on	the	market	under	a	special	name	
in	a	special	pack”.	Article	1	(2)	provides	a	definition	for	“medical	product”.	According	
to	this	definition,	medical	product	is	“any	substance	or	combination	of	substances	pre-
sented	for	treating	or	preventing	disease	in	human	beings.	Any	substance	or	combina-
tion	of	substances	which	may	be	administered	to	human	beings	with	a	view	to	making	
a	medical	diagnosis	or	 to	 restoring,	correcting	or	modifying	physiological	 functions	 in	
human	beings	is	likewise	considered	a	medicinal	product.”17	There	are	also	more	defi-
nitions	 concerning	 the	 different	 kind	 of	medicines	 that	 exist,	 such	 as	 immunological	
medicinal	product,	homeopathic	medicinal	product,	radionuclide	precursor,	etc.	It	can	
easily	be	concluded	that	the	differences	that	exist	between	the	different	kind	of	medi-
cines	is	the	reason	behind	the	heterogeneous	prices	of	medicines.18	The	medical	prod-
ucts	that	are	protected	by	patent	law	are	known	as	“original”	or	“organic”	or	“innova-
tor”	medical	products.19	
																																																						
16	(World	Trade	Organization,	2003).	
17	(Official	Journal	of	the	European	Union,	2001).	
18	(Καφετζής,	2013),	p.	18.	
19		(Viorel,	2015),	p.	10.	
  -7- 
GENERIC	MEDICINES	
Another	 category	of	medicines,	which	 is	 also	well	 –	 known,	 is	 this	 of	“generic	medi-
cines”	or	“generics”.	A	generic	medicine	is	identical	or	bioequivalent	to	a	brand	name	
one	 in	 dosage	 form,	 safety,	 strength,	 route	 of	 administration,	 quality,	 performance	
characteristics	 and	 intended	 use.	 Although	 generics	 are	 chemically	 identical	 to	 their	
branded	counterparts,	they	are	typically	sold	at	substantial	discounts	from	the	brand-
ed	price.20	Generic	medicines	are	legal	copies	of	the	“archetype”	medicines	(the	“pro-
totypes”	or	“innovator”	medicines	or	“originals”).21		
WHY	DO	THEY	EXIST?	
One	of	the	reasons	behind	their	existence	is	of	course	an	economic	one.	Prototypes	are	
really	expensive	and	can	bring	a	 lot	of	profit	 to	pharmaceutical	 companies	 that	own	
them.	 It	 is	 logical	 that	other	pharmaceutical	 companies	want	 a	piece	of	profit	made	
from	a	medicine	 in	 the	pharmaceutical	market.	No	matter	how	protected	medicines	
may	seem	to	be,	patent	is	not	powerful	enough	to	protect	an	archetype	medicine	after	
its	expiration.	Of	course	there	are	also	other	reasons	behind	generics’	existence.			
Pharmaceutical	patents	have	two	special	characteristics.	They	expire	after	an	amount	
of	time	(limited	life	duration	of	approximately	20	years	in	E.U.)	and	they	exist	only	in	
the	country	where	they	were	granted.	Thus,	generic	drugs	can	be	produced	and	sold	
freely	 in	 the	market	 whether	 the	 license	 of	 the	 archetype	medicine	 has	 expired	 or	
whether	a	license	was	not	granted	in	this	specific	country’s	territory.		
To	sum	up,	generics	can	be	produced	when	one	or	more	of	the	following	facts	exist:	
i. The	pharmaceutical	patent	that	protects	the	prototype	has	expired.	
																																																						
20	(U.S.	Department	of	Health	and	Human	Services,	2015).	
21	(Καφετζής,	2013),	pp.	30-31.	
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ii. The	pharmaceutical	 company	 that	produces	a	generic	proves	 that	 there	 is	no	
infringement	 as	 regards	 the	 generic	 and	 the	 prototype’s	 patent	 or	 that	 the	
pharmaceutical	patent	is	null	and	void.	
iii. The	archetype	medicine	was	never	protected	by	a	patent.	
iv. The	archetype	medicine	 is	not	protected	by	patent	 law	 in	 the	 country	where	
the	generic	is	produced.22	
As	 it	 can	 be	 concluded,	 generic	medicines’	 existence	 is	 the	 result	 of	 pharmaceutical	
patents’	existence.	In	my	opinion,	there	is	an	obvious	interaction	between	pharmaceu-
tical	patents	and	generics.	The	end	of	a	patent	is	to	be	considered	the	beginning	of	a	
generic.	If	patents	did	not	exist,	generics	would	not	exist	either.	If	there	was	no	protec-
tion,	chaos	would	exist	and	there	would	be	no	distinction	between	an	archetype	medi-
cine	and	a	generic	one.	Patent	law	provides	the	balance	needed	in	order	to	enhance	a	
healthy	pharmaceutical	 industry	 that	 constitutes	a	 strong	market	not	only	nationally	
but	also	internationally.			
TYPES	OF	GENERICS	
It	is	normal	that	not	all	the	generic	medicines	circulated	in	the	pharmaceutical	market	
are	the	same.	There	are	different	types	of	them:	
i. The	“unbranded”	or	“commodity”	generics.	This	kind	of	generics	is	circulated	in	
the	 pharmaceutical	 market	 with	 the	 International	 Non	 –	 proprietary	 Name	
(INN)	of	 its	active	chemical	 substance	and	 is	defined	by	 the	World	Health	Or-
ganization	(WHO).23		
ii. The	“brand”	generics.	These	generics	are	circulated	in	the	pharmaceutical	mar-
ket	 with	 their	 new	 reserved	 brand	 name	 or	 trademark,	 since	 they	 are	 final	
products.	Brand	generics	have	both	chemical	substance	and	capacity	similar	to	
the	prototype.	
																																																						
22	(Καφετζής,	2013),	pp.	30-31.	
23	(Καφετζής,	2013),	p.	31.	
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iii. The	“copy	products”.	 The	copy	products	have	a	main	difference	compared	 to	
other	generics.	 They	 tend	 to	 copy	a	prototype	medicine	 for	which	a	pharma-
ceutical	 patent	exists	 and	 is	 active.24	 This	 act	 is	 considered	 to	be	an	 infringe-
ment	and	there	are	provisions	that	prohibit	it	in	the	states’	legislation.						
THE	“CLASH”	BETWEEN	GENERICS	AND	PROTOTYPES	
According	to	a	research	group	in	Boston	U.S.,	there	is	no	difference	between	generics	
and	prototypes	and	that	can	affect	 in	a	positive	way	the	 life	of	millions	of	people	all	
over	the	world.	During	the	economic	crisis,	especially	in	countries	such	as	Greece,	the	
existence	of	cheaper	medicines	that	have	the	same	effects	as	the	prototypes	is	more	
than	vital	for	a	patient.	It	is	logical	that	generics	cannot	supplant	the	archetype	medi-
cines	100	per	cent.	Of	course	 the	 important	 thing	 is	 that	 the	patient’s	health	can	be	
secured	with	the	consume	of	“cheaper”	medicines.25	Generics	are	subject	to	the	same	
rules	concerning	the	manufacture	and	pharmacovigilance	and	have	the	same	quality,	
efficiency	and	safety	characteristics	as	the	prototype	medicines.26	
Generic	medicines	seem	to	be	really	famous	in	the	pharmaceutical	market,	since	their	
cost	 is	 lower.	 As	 it	 is	 stated	 by	 the	Medicines	 for	 Europe	 (former	 European	Generic	
Medicines	Association	EGA),	“more	than	56%	of	prescriptions	of	dispensed	medicines	in	
Europe	are	generic	yet	they	account	for	just	22%	of	the	total	expenditure	on	medicines.	
Without	competition	from	generic	medicine	manufacturers,	 this	 level	of	access	would	
cost	Europe	an	additional	€100	billion	every	year.”27	Nowadays,	almost	12	pharmaceu-
tical	companies	that	produce	prototypes	also	operate	subsidiary	companies	that	spe-
cialize	in	the	production	of	generis	(Figure 1: Subsidiary and prototype companies).	
																																																						
24	(Καφετζής,	2013),	p.	32.	
25	(Φαρμάκης,	2012),	p.	53.	
26	(Viorel,	2015),	p.	11.	
27	(Medicines	for	Europe,	n.d.).	
  -10- 
	
	
	
	
	
	
	
It	is	only	logical	that	there	would	be	a	clash	between	prototypes	and	generics.	First	of	
all,	 neither	 science	nor	 legislation	has	defined	whether	 clinical	 trials	 for	 generics	 are	
allowed	to	begin	before	the	exhaustion	of	a	pharmaceutical	patent.28	Whether	such	a	
fact	 is	permitted	a	generic	will	be	able	to	be	circulated	in	the	pharmaceutical	market	
from	the	exact	moment	the	archetype’s	patent	has	expired.	The	WHO	has	not	yet	de-
fined	the	issue.	As	a	result,	the	U.S.	and	Canada	use	the	“Bolar”	provision,	which	allows	
all	the	pharmaceutical	companies	that	manufacture	generics	to	perform	clinical	trials,	
produce	 and	 store	 their	 generics	 before	 the	 exhaustion	 of	 pharmaceutical	 patents.	
However,	such	a	provision	does	not	exist	in	the	E.U..	29	It	is	only	normal	that	there	are	
disputes	between	these	countries.	
																																																						
28	(Γκόλνα,	Κοντιάδης	and	Σουλιώτης	2005),	p.	52.		
29	(Γκόλνα,	Κοντιάδης	and	Σουλιώτης	2005),	p.	52.	
SUBSIDIARY	COMPANY	 PROTOTYPE	COMPANY	
Apothecon	 Bristol	–	Myers	Squibb	
Arcola	Labolatories	 Aventis	(Rhone	Poulenc	Rorer)	
Blue	Ridge	Laboratories	 Aventis	(Hoechst	Marion	Roussel)	
Copley	Phamaceutical	 Aventis	(Hoechst	Marion	Roussel)	
Dista	Products	 Eli	Lilly	
Elkins	–	Sinn		 Wyeth	(American	Home	Products)	
ESI	–	Lederle		 Wyeth	(American	Home	Products)	
Geneva	Pharmaceuticals	 Novartis	
Greenstone	 Pfizer	(Pharmacia	&	Upjohn)	
IPR	Pharmaceuticals	 Astra	Zeneca	
Kanetta	Pharmacal	 Sanofi	Winthrop	
Lederle	Laboratories	 Lederle	Standard	Products	
Penn	Labs	 Glaxo	Smithkline	
Schein	Laboratories	 Bayer	
Figure	1:	Subsidiary	and	prototype	companies		
Source:	(Γκόλνα,	Κοντιάδης	and	Σουλιώτης	2005),	p.	51.	
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On	the	one	hand,	the	European	Union	(EU)	is	treating	generics	in	a	positive	manner.30	
The	reason	behind	this	positive	attitude	is	that	generics	will	decrease	the	cost	of	health	
and	social	 insurances	given	by	the	governments	of	the	member	–	States.31	According	
to	Medicines	for	Europe,	generics	are	the	heart	of	public	health	delivery.	The	5	pillars	
of	 generics	 are	 that	 first,	 generics	 are	 for	 patients	 and	 can	 create	 a	 better-value	
healthcare.	 Second,	 generics	 stand	 for	 quality,	 since	 in	 order	 to	 be	 released	 to	 the	
market	they	have	to	be	approved	and	tested	really	strictly,	according	to	E.U.	and	na-
tional	 regulations	 and	 legislation.	 Third,	 generic	 medicines	 create	 greater	 economic	
value	in	the	supply	of	medicines,	since	fair	and	healthy	competition	in	the	pharmaceu-
tical	market	is	promoted,	in	the	support	of	healthcare	investments’	sustainability	and	
in	 the	promotion	of	a	positive	macroeconomic	 impact	as	regards	the	pharmaceutical	
industry.	Fourth,	generics	enhance	sustainability	as	far	as	safe	and	effective	treatments	
for	European	patients	are	concerned.	Fifth,	the	generic	medicines	industry	is	devoted	
to	partnership	with	the	healthcare	industry	and	the	legislation,	so	that	access	to	medi-
cines	is	ensured	for	every	patient.32			
On	the	other	hand,	this	can	harm	the	profit	made	by	the	pharmaceutical	company	that	
produces	and	sells	the	archetype	medicine.	This	profit	made	is	used	by	pharmaceutical	
companies	 for	 the	 enhance	 of	 research	 to	 create	more	medicines	 and	 improve	 the	
ones	that	already	exist.	Is	it	safe	to	decrease	their	profit	in	such	an	amount	that	further	
research	would	then	be	impossible?	A	prototype	drug	is	the	result	of	years	of	studies,	
research	 and	 money	 spent	 by	 scientists	 and	 pharmaceutical	 companies.	 However,	
there	are	incidents	where	a	pharmaceutical	company	tries	to	secure	profit	by	misusing	
pharmaceutical	patents.		
In	my	 opinion,	 the	 promotion	 of	 generics	 is	 vital	 for	 the	 limitation	 of	monopoly.	 Of	
course,	 pharmaceutical	 companies	 that	 create	 new	 archetype	 medicines	 should	 be	
																																																						
30	(Καφετζής,	2013),	pp.	32-33.	
31	(Καραγιάννης,	2013),	p.	1.	
32	(Medicines	for	Europe,	n.d.).			
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protected	both	economically	and	technologically.	That	is	why	pharmaceutical	patents	
exist.	 Inside	a	market,	 the	stronger	part	cannot	be	equipped	with	all	 the	means	 that	
protect	itself	against	the	weaker	one.	It	is	fair	enough	that	balance	is	provided,	so	that	
both	parties	have	equal	protection	and	opportunities	for	profit.	Since	pharmaceutical	
companies	 that	 can	 create	 new	 innovative	 medicines	 can	 protect	 their	 creations	
through	patents,	the	less	strong	ones	in	the	market	share	should	be	able	to	create	and	
circulate	their	generics	in	it	after	the	expiration	of	the	patent.	If	balance	is	kept,	then	
there	will	be	no	harm	for	the	profit	of	prototypes,	but	also	there	will	be	no	harm	for	
the	 generics	 pharmaceutical	 companies.	 Both	 these	 kinds	 of	 companies	 should	 exist	
for	a	healthy	and	fair	pharmaceutical	market	to	exist	and	flourish.	The	WHO	has	stated	
that	“Competition	is	the	most	powerful	mean	of	politics	used	to	decrease	the	price	of	
medicines	 that	 their	 patents	 have	 expired…”.33
																																																						
33	(Καφετζής,	2013)	pp.	122-123.		
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PATENTS	AND	PHARMACEUTICAL	INDUSTRY	
The	American	virologist	 Jonas	Edward	Salk had	 to	work	 really	hard	 for	almost	 seven	
years	in order	to	discover	the	vaccine	that	can	cure poliomyelitis.	After	World	War	II	
(W.W.II),	polio	was	number	one threat	for	mankind,	since	in	1952,	in	the	U.S.,	58,000	
people	 were	 infected.	 The	 virus	 killed	 3,145 people	 and	 21,269	were	 disabled.	 The	
discovery	of	this	vaccine	in	1955	was	a	huge	relief	for	mankind,	since	millions	of	people	
were	saved	from	certain	death	or	paralysis.	Until	now,	children	from	all	over	the	world	
are	getting	this	specific	vaccine	to	prevent	an	 infection.	 It	can	be	presumed	that	this	
could	make	a	profit	of	billions	of	dollars,	whether	someone	had	protected	it	via	patent	
law.	However,	when	Jonas	Edward	Salk	was	asked	who	owns	the	new	vaccine	for	polio,	
he	answered,	“...I	would	rather	say	the	world.	There	 is	no	patent.	Can	anyone	patent	
the	sun?”.34	
DIFFERENT	TYPES	OF	PHARMACEUTICAL	PATENTS	
Pharmaceutical	patents	are	more	complicated	than	the	other	ones.	That	 is	 logical,	 in	
my	opinion,	considered	that	medicines	are	not	simple	chemical	products,	but,	on	the	
contrary,	they	involve	more	than	one	substances	and	procedures	used	to	manufacture	
them.	 In	 the	pharmaceutical	 industry,	more	 than	one	 types	of	patents	exist	 (Figure	 2:	
Example	of	European	Patent	Certificate).	The	basic	categories	of	pharmaceutical	patents	are:		
																																																						
34	(Μανδραβέλης,	2015).	
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i. The	“composition	patent”	(product	patent).	This	patent	is	the	strongest	one	and	
protects	 the	actual	active	chemical	
substance	 in	 a	 medicine.	 Once	 a	
medicine	 is	protected	by	a	compo-
sition	patent,	no	other	pharmaceu-
tical	 company	 is	 able	 to	 produce,	
sell	 or	 import	 that	 chemical	 sub-
stance.	 If	that	happens,	 it	 is	clearly	
and	 infringement	 of	 the	 patent	
right.35				
ii. The	 “use	 patent”.	 This	 patent	 co-
vers	the	use	of	a	medicine	to	cure	a	
disease.	 It	concerns	the	new	medi-
cal	use	of	an	unprotected	or	an	al-
ready	 protected	 medicine.36	 This	
kind	 of	 right	 can	 be	 protected	 in	
some	 countries,	 such	 as	 the	 U.S.	
and	 Germany,	 but	 unfortunately,	
the	U.K.	and	other	countries	do	not	recognize	it	yet.37		
iii. The	“formulation	–	composition	patent”.	This	patent	concerns	the	pharmaceu-
tical	dosage	form	on	a	medicine.38		
iv. The	“process	patent”.	 This	patent	protects	 the	chemical	or	any	other	process	
that	 is	used	to	manufacture	the	medicine,	while	the	chemical	product	 itself	 is	
not	protected	by	patent	law.	Since	it	is	usually	very	difficult	to	prove	whether	a	
																																																						
35	(MPA,	n.d.).	
36	(Γκόλνα,	Κοντιάδης	and	Σουλιώτης,	2005),	p.	47.	
37	(MPA,	n.d.).		
38	(Γκόλνα,	Κοντιάδης	and	Σουλιώτης,	2005),	p.	47.	
Figure	2:	Example	of	European	Patent	Certificate	
Source:	Elpen	Pharmaceutical	(2016),	
http://www.elpen.gr.	
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pharmaceutical	 company	 has	 been	 using	 a	 patent	 protected	 process,	 many	
countries	have	 legislation	that	provides	a	reversed	burden	of	proof.	Thus,	 the	
company	accused	of	being	 infringing	a	patent	 is	 the	one	responsible	to	prove	
that	such	an	infringement	does	not	actually	exist.39	
v. The	“evergreening	patent”.	This	kind	of	patent	is	granted	to	improved	or	modi-
fied	 medicines	 that	 have	 been	 already	 protected.40	 There	 are	 arguments	
against	the	existence	of	such	patents,	since	the	pharmaceutical	companies	try	
to	 gain	 more	 time	 of	 protection	 by	 producing	 small	 and	 of	 minimum	 im-
portance	changes	to	their	medicines.	A	well-known	example	of	this	kind	of	dis-
pute	 is	 the	Novartis	 v.	 Union	 of	 India	 and	 Others	 case,	 which	was	 finally	 re-
solved	in	2013	by	the	Supreme	Court	of	India.41	According	to	the	judgment,	the	
Court	has	decided	that	the	anti-	cancer	Novartis’s	medicine	“Glivec”	is	not	pro-
tected	 by	 patent	 law,	 according	 to	 India’s	 national	 law,	 since	 it	 is	 not	 a	 new	
medicine,	but	a	new	form	of	the	old	one,42	even	though	the	same	medicine	has	
succeeded	its	protection	as	a	patent	in	several	countries,	such	as	the	U.S.,	Rus-
sia	and	China.	It	is	my	opinion,	that	evergreening	patent	is	an	important	form	of	
pharmaceutical	patent	that	should	not	be	taken	lighthearted.	Regulations	and	
legislation	should	prevent	the	misuse	of	this	patent.	The	abolition	of	this	patent	
is	not	the	solution.	Only	if	countries	create	legislation	that	can	be	fair,	will	bal-
ance	be	preserved.		
PHARMACEUTICAL	SUPPLEMENTARY	PROTECTION	CERTIFICATE	
As	it	has	been	already	mentioned,	the	creation	of	a	medicine	is	not	simple	enough	and	
demands	a	great	amount	of	money	and	constant	research	for	many	years.	Pharmaceu-
																																																						
39	(MPA,	n.d.).			
40	(Καφετζής,	2013),	p.	56.		
41	(Adams	and	Adams,	2013).	
42	(Young,	2013).	
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tical	companies	tend	to	file	a	claim	for	a	pharmaceutical	patent	before	the	release	of	
the	medicine	in	the	market	to	gain	the	appropriate	protection.	In	E.U.,	a	pharmaceuti-
cal	patent’s	life	expectancy	is	20	years.43	That	means	that	if	a	pharmaceutical	company	
is	granted	with	a	patent	before	the	circulation	of	the	medicine,	then	the	time	 limita-
tion	of	20	years	will	end	earlier,	since	the	medicine	would	not	be	released	in	the	mar-
ket	for	the	total	of	years.44	It	is	normal	that	this	fact	cause	unrest	to	the	pharmaceuti-
cal	companies	and	their	investors.	
	To	find	a	fair	solution	to	this	problem,	the	U.S.	and	Japan	created	new	provisions	that	
provided	with	an	extension	of	the	time	limitation	of	the	pharmaceutical	patent.	After	
the	first	step	that	was	made	by	these	countries,	 the	E.U.	was	pressed	to	bring	 in	 life	
similar	measures.	Although	the	European	Patent	Convention	(EPC)	provided	a	fixed	20-
year	patent,	the	E.U.	decided	to	create	a	new	form	of	 intellectual	property	right,	the	
Supplementary	Protection	Certificate	(SPC).	In	1992,	the	EU	Council	created	Regulation	
1768/92	that	provided	SPC	for	the	pharmaceutical	patents	based	on	national	or	Euro-
pean	patents.	The	SPC	has	an	effect	after	the	expiry	of	a	pharmaceutical	patent.	Its	du-
ration	is	equal	to	the	time	spent	between	the	filing	for	a	patent	and	the	first	grant	of	
authorization	 of	 the	market	 of	 the	 European	 Economic	 Area	 (EEA),	 reduced	 by	 five	
years	and	cannot	be	more	than	5	years.45	Of	course,	a	SPC	can	be	granted	only	if	there	
is	a	patent	in	force.46	This	Regulation	was	repealed	by	Regulation	469/2009,	but	there	
were	made	no	significant	changes.	A	Regulation	worth	mentioning	is	1901/2006	con-
cerning	medical	products	for	pediatric	use,	since	it	provided	with	the	extension	of	the	
SPC	for	6	more	months.47			
																																																						
43	(Χρυσάνθης,	2012),	p.	730.	
44	(Viorel,	2015),	p.	18.	
45	(Grubb,	1999),	pp.	148-	150.	
46	(Portal,	1991),	p.	986.	
47	(Viorel,	2015),	p.	19.	
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The	scope	of	the	SPC	is	not	to	extend	the	entire	pharmaceutical	patent,	but	to	preserve	
the	 protection	 given	 to	 the	 product	 covered	 by	 the	 marketing	 authorization.48	 The	
Regulation	tries	to	put	some	quality	and	quantity	limits	regarding	the	SPC.49	The	sales	
of	 the	product	 for	non-medical	use	 is	not	an	 infringement.50	The	subject	–	matter	of	
the	SPC	is	the	“product”;	the	“active	ingredient	or	combination	of	active	ingredients	of	
a	medical	product”.51	Unfortunately,	applicants	 seem	to	be	 reluctant	as	 regards	SPC,	
since	they	are	not	certain	which	is	the	exact	“product”	that	is	protected	by	it;	the	ac-
tive	ingredient	 in	every	possible	formulation	or	 in	only	the	specific	one	for	which	the	
authorization	was	granted?	The	E.U.	Regulation	1768/92	does	not	seem	to	give	a	clear	
answer	to	this	question.	There	is	no	full	explanation	concerning	the	identity	of	the	sub-
ject	–	matter	of	a	pharmaceutical	patent	and	that	of	a	SPC.52		
However,	guidance	seems	to	be	given	about	this	issue	by	Regulation	1610/1996.	If	the	
pharmaceutical	SPC	 is	 interpreted	according	to	the	 latter	Regulation,	then	whether	a	
granted	pharmaceutical	 patent	 covers	 also	other	 forms	of	 the	product,	 the	 SPC	 also	
covers	them,	even	 if	 the	marketing	authorizations	was	for	only	one	form.53	This	 is	of	
great	 importance,	 since	 it	 clears	 all	 the	uncertainty	 that	discouraged	pharmaceutical	
companies	from	applying	for	an	SPC	and	promotes	its	existence.	
Moreover,	 a	 decision	made	 by	 the	 European	 Court	 of	 Justice	 (ECJ)	 has	widened	 the	
possibility	 for	 obtaining	 a	 SPC.	 According	 to	 Neurim	 Pharmaceuticals	 (1991)	 Ltd	 v.	
Comptroller	–	General	of	Patents	case	(19th	of	July	2012),	the	interpretation	of	articles	
3	and	4	of	Regulation	469/2009	is	the	following.	In	case	there	was	an	earlier	marketing	
																																																						
48	(Portal,	1991),	p.	988.		
49	(Viorel,	2015),	p.	21.	
50	(Grubb,	1999),	pp.	222-223.	
51	(Viorel,	2015),	p.	21.	
52	(Viorel,	2015),	p.	21.	
53	(Grubb,	1999),	pp.	222-223.	
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authorization	 for	 the	active	 ingredient	 for	a	different	use	 in	a	different	species,	 then	
this	earlier	authorization	does	not	preclude	the	grant	of	a	SPC	for	a	different	applica-
tion.	But	even	if	there	was	a	case	where	there	was	an	earlier	marketing	authorization	
in	the	same	species,	the	ECJ	made	it	clear	that	the	interpretation	of	the	articles	would	
be	the	same	and	that	the	grant	of	an	SPC	would	be	possible.54	This	European	Court	of	
Justice	 (ECJ)	 decision	 encourages	 even	more	 pharmaceutical	 companies	 to	 invest	 in	
research	and	innovation.		
THE	ECONOMICAL	AND	TECHNOLOGICAL	USE	OF	PHARMACEUTICAL	PATENTS		
The	first	modern	pharmaceutical	
industry	 begun	 to	 exist	 during	
the	 end	 of	 the	 19th	 century,	
when	 scientists	 discovered	 that	
some	raw	materials	had	antisep-
tic	 effects.	 Enterprises	 such	 as	
Ciba	–	Geigy,	Roche	and	Sandoz,	
which	have	first	started	as	family	
businesses	 in	 Switzerland,	
moved	 to	 the	 production	 of	
pharmaceutical	 substances	 and	
became	 some	of	 the	most	pow-
erful	pharmaceutical	companies.	
One	 of	 the	 reasons	 behind	 the	
massive	 evolution	 of	 pharma-
ceutical	industry	was	W.W.II	and	the	urgent	need	for	antibiotics.55		
As	regards	the	pharmaceutical	industry,	patents	normally	equal	the	product,	and	pro-
																																																						
54	 (Neurim	 Pharmaceuticals	 (1991)	 Ltd	 v.	 Comptroller	 -	 General	 of	 Patents,	
2012).	
55	(Φαρμάκης,	2012),	pp.	12-13.	
Figure	3:	Phases	of	a	medicine's	production	
Source:	The	European	Federation	of	Pharmaceutical	Industries	
and	Associations	(EFPIA),	2016,	
http://www.efpia.eu/uploads/Modules/Documents/the-
pharmaceutical-industry-in-figures-2016.pdf.	
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tect	the	extensive	investment	in	research	and	clinical	testing	required	before	placing	it	
on	the	market.56	It	is	thought	that,	for	the	creation	of	a	new	and	successful	medicine,	
scientists	 need	 to	 spend	 approximately	 10	 to	 15	 years	 for	 studies,	 research,	 clinical	
tests,	price	 fixation	etc.57	 (Figure	 3:	 Phases	 of	 a	medicine's	 production).	During	 these	years,	
more	 than	hundreds	 of	 people	 are	 obliged	 to	work	 on	 this	 project	 to	 accomplish	 it.	
From	every	5,000	to	10,000	pharmaceutical	products,	that	insert	research	and	produc-
tion,	only	one	of	them	makes	it	successfully	to	the	pharmaceutical	market	and	is	com-
mercially	exploited.	The	amount	of	money	needed	from	the	beginning	of	research	until	
the	 medicine	 joins	 the	 market	 is	 considered	 to	 be	 approximately	 $800,000,000	 to	
$1,000,000,000	per	medicine.	All	these	huge	capitals	are	mainly	private	and	it	 is	only	
logical	that	they	head	towards	investments	that	can	secure	pure	profit.58		
	Pharmaceutical	patents	have	a	technological	reason	behind	their	existence.	According	
to	Patent	Law,	not	only	in	Greece,	but	almost	in	every	country	around	the	world,	a	pa-
tent	must	describe	the	invention	in	details	and	include	all	these	features	that	make	it	
so	unique,	innovative	and	new.	It	can	be	published	months	after	the	claim	of	its	grant	
is	filed.	After	the	publication,	researchers	and	scientists	are	allowed	to	study	it.	Due	to	
that,	 technological	 information	 is	 spread	 to	 others	 and	 so	 does	 knowledge	 and	 the	
spirit	 of	 innovation	 and	 healthy	 competition	 between	 pharmaceutical	 companies.59	
Moreover,	the	fact	that	patents	grant	a	pharmaceutical	company	the	right	to	protect	
its	pharmaceutical	substances	for	a	period	of	time,	operates	as	a	reward	towards	their	
efforts	and	promotes	their	motive	for	further	research	and	innovation.60		
Patent	 protection	 for	 chemical	 and	 pharmaceutical	 products	 is	 especially	 important,	
																																																						
56	(Lehamn,	2003),	p.2. 	
57	(Φαρμάκης,	2012),	p.	14.	
58	(Μπάλλας,	2010),	p.	3.	
59	(Μπάλλας,	2010),	pp.	3-4.	
60	(Φαρμάκης,	2012),	p.	26.	
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compared	to	other	industries,	because	the	actual	manufacturing	process	is	often	easy	
to	replicate	and	can	be	copied	with	a	 fraction	of	 the	 investment	of	 that	 required	 for	
the	research	and	clinical	testing.	A	medicine,	of	course,	cannot	be	protected	forever.	
After	the	expiry	of	the	patent,	the	medicine	falls	into	the	public	domain	and	everyone	
is	 free	 to	make	use	of	 it.	 That	 seems	 to	be	unfair,	 since	 a	 company	has	 spent	 great	
amounts	of	money,	as	it	was	mentioned	above,	to	create	the	medicine.		
The	imitation	and	the	copy	of	a	successful	medicine	is	not	only	easy,	but	also	cheap	as	
a	process,	since	the	cost	of	a	medicine’s	production	is	lower	than	the	investment	made	
for	its	research	in	the	first	place.	As	a	result,	the	risk	that	is	taken	by	an	investment	to	
be	easily	imitated	later	by	other	companies	and	lose	a	lot	of	money,	is	a	risk	that	dis-
courages	new	 investors	 from	offering	money	 to	 innovation	 and	new	 research	 in	 the	
pharmaceutical	 industry.61	 That	 incident	 can	 only	 cause	 problems	 to	 patients	 -	 con-
sumers	and	healthcare,	since	pharmaceutical	companies	and	scientists	are	discouraged	
from	trying	to	 find	the	cure	for	diseases	that	make	people	suffer	or	help	patients	be	
more	comfortable	thanks	to	new	medicines	which	are	more	effective	and	suitable.	The	
research	of	new	pharmaceutical	substances	is	sure	to	hide	a	great	risk	for	pharmaceu-
tical	 companies	 and	 so	 many	 European	 companies	 tend	 to	 transfer	 to	 the	 United	
States	(U.S.),	since	they	provide	a	friendly	environment	that	welcomes	companies	and	
their	investments.62	
Patents	 in	 the	pharmaceutical	 industry	are	 trying	 to	 reverse	 this,	 since	 they	give	 the	
investors	 the	 protect	 they	 need.	 The	 “pharmaceutical	 patent”	 gives	 a	 company	 the	
right	to	have	a	monopoly	as	far	as	the	specific	medicine	is	concerned	and	thus	only	this	
company	can	make	profit	from	its	sale	in	the	pharmaceutical	market.	After	that	it	be-
comes	clear	that	pharmaceutical	patents	do	also	have	an	economic	use.	
	
																																																						
61	(Μπάλλας,	2010),	p.	3.	
62	(Φαρμάκης,	2012),	p.	14.	
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COMMERCIAL	EXPLOITATION	OF	PHARMACEUTICAL	PATENTS	
The	pharmaceutical	market	is	one	of	the	most	powerful	markets	worldwide	and	should	
not	be	taken	light	–	hearted.	According	to	European	Federation	of	Pharmaceutical	In-
dustries	 and	 Associations	 (EFPIA)	 report,	 27	million	 euros	 were	 spent	 in	 the	 E.U.	 in	
2010	 in	 the	departments	of	 research	and	development	of	 the	pharmaceutical	 indus-
try.63	It	is	essential	to	mention	that	no	pharmaceutical	product	is	allowed	to	be	circu-
lated	 in	 the	 European	 pharmaceutical	 market	 unless	 a	 marketing	 authorization	 has	
been	first	granted	(article	3(1)	Regulation	726/2004).64		
THE	PHARMACEUTICAL	MARKET	
Pharmaceutical	 market	 seems	 to	
behave	 differently	 compared	 to	
other	markets	(Figure	4:	The	European	
Pharmaceutical	 Industry).	 One	 of	 the	
reasons	 behind	 this	 conclusion	 is	
the	 fact	 that	 it	 is	 characterized	by	
some	 special	 features	 which	 are	
not	met	 in	other	markets,	 since	 it	
is	a	subcategory	of	 the	healthcare	
market.65	 The	most	 important	dif-
ference	that	is	spotted	in	the	glob-
al	pharmaceutical	market	and	that	
distinguishes	 it	 from	 all	 the	 other	
markets	 is,	 according	 to	my	 opin-
																																																						
63	(Φαρμάκης,	2012),	p.	27.	
64	(Κρεμαλής,	2011),	p.	735	
65	(Καφετζής,	2013),	p.	18.	
Figure	4:	The	European	Pharmaceutical	Industry	
Source:	The	European	Federation	of	Pharmaceutical	Indus-
tries	and	Associations	(EFPIA),	2016,	
http://www.efpia.eu/uploads/Modules/Documents/the-
pharmaceutical-industry-in-figures-2016.pdf.	
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ion,	the	almost	full	separation	between	consumers	and	purchasers	of	the	product.66		
PHARMACEUTICAL	MARKET’S	CHARACTERISTICS	
First	 of	 all,	pharmaceutical	market	 is	 a	 part	 of	 the	 healthcare	market	 which	 is	 con-
trolled	by	“information	asymmetry”.	By	this	term,	it	is	meant	that,	most	of	the	times,	
the	patient	 is	not	capable	of	understanding	 the	medical	condition	nor	 the	 treatment	
needed.	People	who	have	not	gained	medical	experience	by	having	health	studies	are	
unable	to	control	a	situation	of	illness	and	to	decide	the	necessary	treatment.	Thus,	a	
knowledge	asymmetry	can	be	seen	between	patients	–	consumers	and	medical	practi-
tioners	–	producers.	Due	to	the	existence	of	that	asymmetry,	patients	–	consumers	are	
not	 the	ones	 in	 charge.	On	 the	 contrary,	 the	 leader	 seems	 to	be	 the	medical	practi-
tioner	–	producer,	who	prescribes	 the	appropriate	medicine	needed	for	a	cure	to	be	
achieved	 (“consumer	 sovereignty”).	 Because	of	 this	 gap	 that	 exists	 between	patients	
and	 medical	 practitioners,	 an	 “agency	 relationship”	 is	 built.	 Patients	 cannot	 act	 by	
themselves	as	 individuals.	They	are	“represented”	by	their	medical	practitioners	who	
actually	choose	the	best	treatment	for	them,	on	behalf	of	them.	Unfortunately,	there	
are	no	clear	choices	which	are	made	exclusively	by	consumers	as	it	happens	in	the	free	
market.	67	
Secondly,	 there	 is	 also	 the	 “moral	 hazard”.	 The	 insurance	 company	 or	 organization,	
according	to	each	country’s	legislation,	is	obliged	to	return	to	the	patient	the	economic	
burden	caused	due	 to	 the	 illness,	 the	value	of	 the	medicine.	Neither	 the	patient	nor	
the	medical	practitioner	care	enough	about	the	costs	of	a	medical	treatment,	since	the	
burden	is	to	be	carried	by	a	third	party	(“third	party	payer”).			
Last	but	not	least,	there	are	also	the	positive	and	negative	“externalities”	that	concern	
the	 costs	 and	 profits	 made	 by	 medical	 practitioners	 and	 patients.	 They	 move	 from	
them	to	both	society	and	the	environment	and	provoke	changes	to	them.	For	example,	
																																																						
66	(Καφετζής,	2013),	p.	18		
67	(Καφετζής,	2013),	pp.	13-14.	
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vaccination	for	the	prevent	of	an	epidemic	is	an	externality	that	can	protect	a	person	
from	getting	sick	or	from	transmitting	a	disease	to	another	person.68	
In	 my	 opinion,	 these	 characteristics	 are	 the	 main	 reason	 behind	 the	 failure	 of	
healthcare	market	as	 it	 is	structured	and	the	reason	why	the	right	 in	health	must	be	
treated	as	a	free	and	public	right.			
DEMAND	AND	OFFER	IN	THE	PHARMACEUTICAL	MARKET	
It	 is	already	mentioned	 that	 in	 the	pharmaceutical	market	 the	patient	–	consumer	 is	
not	 the	one	who	 takes	 the	decision	 concerning	 the	 choice	 of	medicines.	Demand	 in	
pharmaceutical	market	is	not	estimated	only	by	consumers,	but	by	many	factors.	Med-
ical	practitioners,	insurance	organizations,	pharmacists	and	the	patient	interact.	69		As	a	
result,	 “imperfections”	 are	 caused	 in	 the	 pharmaceutical	market	 that	 affect	 demand	
and	cause	perfect	competition	to	become	unbalanced.		
Demand	is	split	into	four	dimensions:	
i. To	the	“customer”,	who	is	the	medical	practitioner,	
ii. To	 the	“payer”,	who	 is	 the	 insurance	company	or	organization,	depending	on	
the	country’s	legislation,	
iii. To	the	“distributor”,	who	is	the	pharmacist	and	
iv. To	the	“consumer”,	who	is	the	patient.70	
It	 is	only	logical,	to	me,	that	demand	numbers	cannot	be	granted	with	stability,	since	
there	are	many	factors	that	can	cause	the	scale	to	move	towards	different	directions.	
Diseases	that	torture	patients	are	not	always	the	same	and	can	change,	depending	on	
the	patient’s	age	and	the	period	(for	example	seasonal	influenza).		
																																																						
68	(Καφετζής,	2013),	p.	14.	
69	(Καφετζής,	2013),	p.	20.	
70	(Καφετζής,	2013),	p.	21.	
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This	is	also	boosted	by	these	facts.	Consumption,	thus	demand,	in	the	pharmaceutical	
market	is	affected	by	five	factors:	
i. By	 the	 factor	 that	 finances	 the	 pharmaceutical	market,	 for	 example	 the	 gov-
ernment,	the	insurance	organization	or	even	the	patients	themselves,	whether	
they	pay	for	the	medication.	
ii. By	demographic	factors,	since	the	rise	of	life	expectancy	increases	the	demand	
of	medicines	 for	 elderly	 people	who	need	 them	 in	 greater	 and	more	 specific	
amounts.	
iii. By	epidemiological	 factors,	 since	diseases	are	 the	main	cause	 that	pushes	pa-
tients	to	the	pharmaceutical	market.	
iv. By	social	and	economic	 factors.	Ever	since	poverty	has	started	to	eliminate	 in	
many	social	statuses,	people	are	more	capable	to	afford	medication.	Moreover,	
the	dissemination	of	the	need	of	education	has	played	an	important	role	in	the	
change	of	pharmaceutical’s	demand.	This,	on	 the	other	hand,	was	 impossible	
when	people	were	not	as	educated	and	as	sensitized	as	today	and	is	still	impos-
sible	in	less	developed	countries	where	poverty	thrives.	
v. By	 healthcare	 factors.	 Nowadays,	more	 and	more	medical	 practitioners	 exist	
and	more	medicines,	 that	 cure	 illnesses	 that	 used	 to	 be	 fatal,	 appear.	 Thus,	
people	tend	to	care	more	about	their	health	and	their	treatment.71	
As	 far	as	offer	 is	 concerned,	 there	are	also	some	particularities.	The	main	one	 is	 the	
result	 of	monopoly	 that	 is	 granted	 to	 pharmaceutical	 companies	 by	 pharmaceutical	
patents.72	 It	becomes	clear,	more	 than	once,	 in	my	opinion,	 that	pharmaceutical	pa-
tents	do	not	only	grant	companies	with	rights	 that	make	them	feel	secure,	 they	also	
have	an	economic	use.	They	built	an	entire	market	 that	 is	adjusted	by	 this	 right	and	
could	possible	fall	off	like	a	paper	castle	once	this	right	is	taken	away.	It	is	vital	that	it	is	
well	understood	that	balance	in	the	pharmaceutical	market	is	kept	by	a	very	thin	rope.	
																																																						
71	(Καφετζής,	2013),	p.	22.	
72	(Καφετζής,	2013),	p.	23.	
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The	main	characteristics,	that	adjust	offer	 in	the	pharmaceutical	market	are	the	ones	
mentioned	below:	
i. The	minimize	of	costs	and	the	maximize	of	 investments	 to	succeed	 long-term	
profit.	
ii. Mergers	and	acquisitions	in	the	global	pharmaceutical	market	and	
iii. The	classification	of	pharmaceutical	companies	into	three	categories.	First,	the	
big	 multinational	 pharmaceutical	 companies,	 which,	 of	 course,	 are	 the	 most	
powerful	ones.	Second,	the	pharmaceutical	companies	that	are	capable	of	the	
produce	 of	 prototypes,	 but	 focus	 only	 in	 the	 produce	 of	 generics.	 Third,	 the	
pharmaceutical	 companies	 that	 operate	 in	 a	more	 “family	 business”	manner	
and	are	not	as	powerful	as	the	previous	ones.73	
To	 sum	 up,	according	 to	 the	WHO,	 the	adjustment	 of	 the	 pharmaceutical	market	 is	
characterized	by	 three	 facts.	 First,	by	 the	“product	 regulation”,	where	medicines	are	
checked	and	evaluated	before	and	after	 they	enter	 the	market.	 Second,	by	 the	 “ad-
justment	of	the	manufacture,	import	and	distribution”	of	the	medicines	in	the	market.	
Third,	by	the	“adjustment	of	commercial	promotion	of	medicines”.74	
THE	PHARMACEUTICAL	INDUSTRY	IN	GREECE	
In	Greece,	 in	2013,	56	multinational	and	50	national	pharmaceutical	 companies,	120	
medicine	warehouses,	27	medicine	partnerships	and	11,000	pharmacies	existed,	so	it	
can	 be	 concluded	 that	 pharmaceutical	 industry	 is	 vital	 for	Greece’s	 economic	 devel-
opment.75	According	to	facts	given	by	the	Panhellenic	Union	of	Pharmaceutical	Indus-
																																																						
73	(Καφετζής,	2013),	pp.	25-26.	
74	(Καφετζής,	2013),	pp.	26-27.	
75	(Healthmag.gr,	2016).	
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try	 (PEF),	 some	 examples	 of	 Greek	 pharmaceutical	 companies	 are	 Adelco,	 Demo,	
Elpen,	UNI	–	PHARMA,	VIANEX.76	
THE	GREEK	PHARMACEUTICAL	MARKET	
	The	Greek	pharmaceutical	 industry,	even	though	
Greece	 is	 in	 economic	 depression,	 is	 not	 limited.	
Greek	 companies	 produce	 various	 generic	 medi-
cines	 that	 are	 exported	 to	 countries	 not	 only	 in	
Europe,	but	in	four	continents.	77	However,	Greek	
pharmaceutical	 companies	 do	 not	 only	 produce	
generics.	They	also	create	new	medicines.	(Figure	5:	
Example	of	Greek	Pharmaceutical	 Patent	Certificate).	 	For	
example,	 the	 Greek	 pharmaceutical	 company	
Elpen	has	a	very	strong	intellectual	proper-
ty	 portfolio.	 “Elpenhaler”,	 an	 inhaler	 de-
vice,	 has	 been	 granted	more	 than	 90	 pa-
tents	 in	 many	 countries	 both	 European	
and	non-European.78		
“SALOSPIR”,	a	well-known	medicine,	was	created	by	the	Greek	company	UNI	–	PHAR-
MA.	The	decision	made	by	the	Greek	Court	concerning	a	dispute	between	BAYER	AG.	
and	UNI	 –	 PHARMA	 S.A.	 cannot	 be	 forgotten,	 since	 it	 is	 positive	 towards	 the	Greek	
pharmaceutical	company	and	analyzes	 in	depth	and	 in	a	correct	manner	 the	difficult	
issues	that	concern	medicines,	their	packages,	how	consumers	interact	with	the	view	
of	 the	medicine’s	package	and	how	all	 these	 can	affect	pharmaceutical	 competition.	
The	main	conclusion	made	by	this	judgement	is	that	pharmaceutical	products’	reputa-
																																																						
76	(Πανελλήνια	Ένωση	Φαρμακοβιομηχανίας,	n.d.).		
77	(Elpen,	n.d.).	
78	(Elpen,	n.d.).	
Figure	5:	Example	of	Greek	Pharmaceutical	Patent	
Certificate	
Source:	Elpen	Pharmaceutical	(2016),	
http://www.elpen.gr.	
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tion	is	built	by	their	name	and	not	by	their	packaging	colors,	as	BAYER	tried	to	state.79	
This	judgment	can	and	will	have	a	major	effect	on	pharmaceutical	competition	law	not	
only	in	Greece,	but	also	in	E.U.	In	my	opinion,	it	is	a	huge	win	for	a	Greek	pharmaceuti-
cal	company	against	a	colossus	German	one	in	today’s	Greece,	despite	the	economic	
depression	 that	 limits,	 in	 most	 cases,	 its	 pharmaceutical	 industry’s	 capability.	 Thus,	
Greek	pharmaceutical	market	is	an	active	one	that	also	contributes	in	the	global	phar-
maceutical	industry.		
THE	“GENERIC	PARADOX”		
Many	Greek	pharmaceutical	companies	focus	on	the	production	of	generics.	Generics	
can	 provide	 high	 profit	 due	 to	 their	 lower	 price	 and	 cost	 of	manufacture.80	 Generic	
medicines	enhance	competition,	since	they	are	cheaper	than	the	prototypes	but	have	
the	same	effects	as	them.	As	a	result	a	lot	of	people	prefer	to	purchase	them	instead	
of	 the	more	 expensive	 archetype	medicine.	 The	 E.U.	 also	 tries	 to	 promote	 generics	
over	prototypes	 in	 a	way	 to	decrease	 the	member	–	 States	 costs	 in	 social	 insurance	
and	to	use	these	capitals	in	order	to	enhance	innovation	and	as	a	result	competition.81	
Unfortunately,	there	is	the	“generic	paradox”.	According	to	this	phenomenon,	even	if	
there	is	a	huge	insertion	of	generics	 in	the	pharmaceutical	market,	that	could	not	ef-
fect	so	massively	competition	and	as	a	result	the	prices	of	the	prototypes.	It	could	only	
just	slow	down	the	rhythm	of	the	increase	of	prices.	The	reason	behind	this	paradox	is	
that	even	though	generics	exist	 in	huge	numbers	 in	 the	market,	 their	purchase	 is	ef-
fected	by	the	medical	practitioners’	prescriptions	and	not	by	consumers,	as	 it	has	al-
ready	been	mentioned.	It	is	prescription	the	factor	that	gives	form	to	demand.82	
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PHARMACEUTICAL	PATENTS	AND	COMPETITION	LAW	
Even	though	China	and	India	have	tried	to	progress	
during	the	last	years,	the	biggest	part	of	the	global	
pharmaceutical	 market	 is	 in	 Europe	 and	 the	 U.S.	
(Figure	 6:	 The	World	 Pharmaceutical	 Industry	 (2010)).	 The	
U.S.	controls	the	38,1%	of	the	global	pharmaceuti-
cal	 market,	 Europe	 the	 36,1%,	 while	 Japan	 and	
other	countries	only	the	7,7%	and	18,1%.	Though	it	
seems	 like	 the	 U.S.	 pharmaceutical	 market	 has	
flourished	 during	 the	 last	 two	 decades	 (Figure	 7:	
Sales	 in	 the	 Pharmaceutical	 Market	 (2015)),	 since	 many	
companies	 were	 transferred	
there,	 on	 the	 contrary,	 the	
European	 pharmaceutical	
market’s	 production	 has	 in-
creased	 compared	 to	 the	 investments	made	 and	 it	 could	 even	be	 stronger	 than	 the	
U.S.	market.83		
One	of	competition	goals	is	to	make	sure	that	pharmaceutical	companies	can	enter	a	
market	which	is	large	enough	not	only	to	bear	the	costs	of	developing	new	medicines,	
but	also	 to	make	enough	profit,	 so	 that	more	 research	and	development	 is	 inspired.	
The	definition	of	healthy,	fair	and	workable	competition	does	not	exist	in	the	Treaty	of	
Functioning	of	 the	European	Union	 (TFEU),	but	 can	be	concluded	by	 the	case	 law	of	
the	ECJ.	For	a	competition	to	be	effective	it	is	essential	that	the	market	is	structured	in	
a	 competitive	 manner.	 A	 workable	 competition	 must	 be	 in	 position	 to	 accomplish	
three	main	results:	
i. “Allocate	efficiency”	(price	fixation),	
ii. “Productive	efficiency”	(lower	prices	that	are	closer	to	factory	prices)	and	
																																																						
83	(Φαρμάκης,	2012),	p.	17.	
Figure	6:	The	World	Pharmaceutical	Industry	(2010)	
Source:	Φαρμάκης	Κωνσταντίνος,	
http://nemertes.lis.upatras.gr/jspui/bitstream/10889/5280/1/Farm
akis%20Constantinos.pdf,	p.	17.	
	
	
  -31- 
iii. “Innovative	efficiency”	(more	research).84		
	The	 EU	 is	 trying	 to	 accom-
plish	 this	 by	 many	 means.	
The	 first,	 and	 the	 most	 im-
portant	 one,	 in	 my	 opinion,	
is	the	harmonization	of	legis-
lation,	 concerning	 pharma-
ceutical	 patents	 and	 compe-
tition	 law,	 throughout	 the	
E.U.	member	 –	 States.	The	
second,	 which	 has	 already	
been	analyzed	in	the	previ-
ous	chapter,	is	that	the	E.U.	
pharmaceutical	 industry	
recognizes	 a	 special	 privi-
lege	for	pharmaceutical	patents,	the	SPC.	The	third	is	that	E.U.	competition	law	strives	
to	promote	single	market	integration,	so	that	pharmaceutical	market	will	not	be	divid-
ed	 in	 national	 level.85	 Of	 course,	 the	 existence	 of	 harmonized	 legislation	 concerning	
patent	law	and	especially	pharmaceutical	law	is	also	the	key	behind	the	success	of	the	
above.	The	link	between	patents	and	competition	is,	nevertheless,	more	obvious	than	
ever.	 Provided	 there	 is	 effective	 pharmaceutical	 patent	 protection	 in	 E.U.,	 would	
pharmaceutical	market	be	productive	and	profitable	for	all	interested	in	it.	Maire	Ge-
oghegan	–	Quinn,	E.U.	Commissioner	for	Research	has	claimed	that	“innovation	is	vital	
for	a	successful	modern	economy,	it	is	as	important	as	water	for	life…”.86		
On	the	contrary,	there	is	an	opinion	which	argues	with	the	above.	There	are	critics	who	
																																																						
84	(Σταματούδη,	2006),	p.	39.	
85	(Hancher,	1992),	p.	387.	
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Figure	7:	Sales	in	the	Pharmaceutical	Market	(2015)	
Source:	The	European	Federation	of	Pharmaceutical	Industries	and	
Associations	(EFPIA),	2016,	
http://www.efpia.eu/uploads/Modules/Documents/the-
pharmaceutical-industry-in-figures-2016.pdf.	
	
	
  -32- 
question	the	link	between	patents,	innovation	and	healthy	competition	in	the	field	of	
pharmaceutical	market.	They	claim	that	there	is	no	proof	of	a	link	between	them	and	
that	 pharmaceutical	 companies	 do	not	 focus	 on	 innovation	 and	 the	development	 of	
the	most	urgent	and	lifesaving	medicines,	but	on	the	development	of	the	most	profit-
able	 ones.	 It	 is	 true	 that	 in	 the	 U.S.	 pharmaceutical	 market	 the	 profit	 made	 of	 the	
blockbuster	medicines	 is	 immense.87	 Professor	 Sager	 has	 pointed	 out	 that	 since	 pa-
tents	 are	 extended	 and	 general,	 pharmaceutical	 companies	 are	 used	 to	 operate	 like	
monopolies.88		
An	 issue	 that	 enhances	 this	belief	 is	 that	of	“Daraprim”	medicine	 (U.S.).	Daraprim	 is	
used	by	people	that	are	infected	by	IHV,	produced	by	the	Turing	Pharmaceutical.	This	
medicine	 is	62	years	old	and	 is	used	against	 toxoplasmosis.	Unfortunately,	 the	phar-
maceutical	company	has	decided	to	increase	its	cost	from	13,50$	to	750$,	because	the	
previous	 price	 could	 not	 make	 enough	 profit	 for	 the	 company.	 Thus,	 in	 India	 a	 pill	
could	 cost	 around	 $0.05,	 in	 U.K.	 around	 $0.66,	while	 on	 the	 other	 hand	 in	 the	U.S.	
$750!	Even	 though	this	medicine	 is	not	protected	by	patent	 law,	 the	pharmaceutical	
company	has	indeed	a	great	monopoly	over	it,	since	other	pharmaceutical	companies	
need	 to	 file	 an	“abbreviated	new	drug	application”	 (ANDA)	 that	 could	allow	 to	 their	
generics	to	register	 in	the	U.S.	pharmaceutical	market.	Unfortunately,	no	company	 is	
interested	in	that,	because	of	the	small	market	share	that	this	medicine	represents	and	
of	the	risk	that	Turing	Pharmaceutical	could	possibly	lower	the	price	again	for	profit.89		
In	my	opinion,	 the	 reason	behind	 the	 existence	of	 pharmaceutical	 patents	 is	 indeed	
the	promotion	of	 innovation	and	fair	and	healthy	competition.	Even	though	numbers	
seem	to	show	that	pharmaceutical	companies	earn	great	amount	of	money	due	to	pa-
tents	and	the	monopoly	that	they	create,	it	is	not	to	be	forgotten	that	they	also	spent	
enormous	amounts	in	research	and	innovation.	Only	if	there	is	the	feeling	of	security,	
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will	pharmaceutical	companies	be	able	 to	 invest	 into	research	and	medicines.	Other-
wise,	 high	 risk	 investments	 will	 discourage	 the	 fund	 owner’s.	 Balance	 between	 re-
search	and	 innovation	 in	medicines	and	 fair	 competition	will	be	destroyed	with	 fatal	
results	for	healthcare.	It	is	imperative	that	balance	is	the	beginning	and	the	end	of	eve-
ry	new	measure	taken	to	manage	the	pharmaceutical	market	and	its	areas	and	not	to	
wrong	 neither	 patients	 –	 consumers’	 nor	 pharmaceutical	 companies’	 interests	 and	
prerogatives.			
PHARMACEUTICAL	PATENTS	AND	PARALLEL	IMPORT	
Another	important	key	that	plays	a	crucial	role	in	the	European	pharmaceutical	market	
is	medicines’	prices.	This	 issue	has	 indeed	created	a	division	through	the	E.U.	market	
that	has	been	expressed	through	parallel	import	(Figure	8:	Parallel	Import	in	the	E.U.	Pharma-
ceutical	Industry).		
There	are	two	types	of	pharmaceutical	parallel	import:	
i. The	 first	 type	 concerns	
the	phenomenon	of	par-
allel	 imports.	 According	
to	 it,	 a	medicine	 is	 pro-
duced	 in	 two	 or	 more	
different	 countries	 and	
is	 then	 sold	 in	 different	
“ex-factory	 prices”.	
Sometimes	 these	 facto-
ries	 are	 owned	 by	 the	
same	 pharmaceutical	
company	that	also	owns	
the	 pharmaceutical	 pa-
tent.	The	medicine	 is	purchased	by	a	supplier	 in	a	country	with	 the	 lower	ex-
factory	 price	 and	 is	 exported	 towards	 the	 country	with	 the	 higher	 ex-factory	
price.		
Figure	8:	Parallel	Import	in	the	E.U.	Pharmaceutical	Industry	
Source:	The	European	Federation	of	Pharmaceutical	Industries	
and	Associations	(EFPIA),	2016,	
http://www.efpia.eu/uploads/Modules/Documents/the-
pharmaceutical-industry-in-figures-2016.pdf.	
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ii. The	second	type	concerns	the	phenomenon	of	parallel	re-imports.	According	to	
it,	the	same	pharmaceutical	company	exports	a	medicine	in	a	lower	price	than	
the	price	 that	 it	 is	 sold	 inside	 the	 country.	 The	price	 is	 adjusted	 to	 the	 lower	
price	that	exists	in	the	import	–	country.	It	is	also	possible	that	the	pharmaceu-
tical	merchants	of	the	import	–	country	do	intend	to	re-export	the	medicine	in	
order	to	gain	more	profit.90		
Unfortunately,	these	kinds	of	movements	have	many	side-effects.	Shortages	 in	medi-
cines	 can	 be	 detected	 in	 the	 re-export	 –	 countries	 and	 identical	 medicines	 are	 re-
imported	from	low	cost	countries	to	higher	cost	ones	in	order	to	make	more	profit	by	
the	lower	price.	The	expiration	of	a	series	of	patents	does	not	help	with	this	problem.	
Generic	competition	and	the	positive	position	of	the	E.U.	and	ECJ	towards	them	also	
point	 to	 a	more	 fair	 and	 healthy	 pharmaceutical	market.91	 A	market	 that	 seems,	 as	
years	 are	 passing	 by,	 that	 is	 healthier,	 united	 and	 not	 the	 privilege	 of	 a	 few	 strong	
companies,	and	that	cares	more	deeply	for	the	better	good	of	people.	After	all,	phar-
maceutical	 industry’s	goal	should	be	the	ensuring	of	people’s	health	and	the	 fight	of	
illnesses,	since	the	most	important	good	in	a	person’s	life	is	health	and	well-being.	The	
E.U.	is	taking	into	consideration	both	consumers’	and	the	companies’	rights.		
	According	to	the	E.U.	law,	there	are	two	sets	of	rules	relevant	to	patents:	the	competi-
tion	rules	and	the	rules	on	the	free	movement	of	goods.	The	EU	Competition	Law	tries	
to	protect	competition	in	E.U.	market	and	to	promote	the	efficient	use	and	dissemina-
tion	of	goods	and	services	 throughout	 the	E.U.	 It	 cannot	be	omitted	 that	one	of	 the	
fundamental	 objectives	 of	 the	 E.U.	 Treaty	 was	 the	 creation	 of	 a	 Common	 Market,	
where	goods	will	be	circulated	freely,	with	only	a	 few	exceptions.92	One	of	 these	ex-
ceptions	is	that	E.U.	law	seems	to	recognize	the	existence	of	patents	given	by	member	
–	States	with	some	 limitation.	There	are	some	concepts	 that	Courts	should	 take	 into	
																																																						
90	(Γκόλνα,	Κοντιάδης	and	Σουλιώτης,	2005),	p.	29.			
91	(Hancher,	1992),	pp.	389-390.		
92	(Travers,	1998),	p.	47.		
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consideration	when	deciding	about	such	conflicts:	
i. The	“dichotomy”	between	the	existence	and	the	exercise	of	patents,	
ii. The	specific	“subject	–	matter”	of	the	patent	and	
iii. The	exhaustion	of	patent	rights.93	
An	 important	 case	 concerning	 the	 issue	of	 parallel	 import	 is	 the	Centrafarm	BV	and	
Adriaan	da	Peijper	v.	Sterling	Drug	INC	case.	The	Sterling	Drug	company	was	granted	
patents	 for	both	the	U.K.	and	Netherlands	regarding	a	medicine	against	urinary	tract	
infection	 (UTI).	 The	 same	medicine	 was	 sold	 in	 the	 U.K.	 for	 half	 price	 compared	 to	
Netherlands,	since	the	U.K.	had	strict	legislation	concerning	pharmaceuticals’	price	fix-
ing.	Centrafarm	company	was	specializing	in	pharmaceuticals’	parallel	 import	and	im-
ported	a	great	amount	of	this	medicine	in	Netherlands	with	the	intension	of	selling	it.	
Sterling	Drug	tried	to	block	this	by	using	its	Netherlandish	patent.	According	to	the	ECJ,	
the	scope	of	patent	is	the	reward	of	the	inventor	for	the	creation.	The	pharmaceutical	
patent’s	owner	has	 the	exclusive	 right	 to	 circulate	 the	medicine	 in	 the	E.E.A..	 In	 this	
case,	Sterling	Drug	was	rewarded	for	the	creation	of	the	medicine	by	putting	it	in	the	
U.K.’s	market	and	making	profit	out	of	it,	so	its	right	was	exhausted.	The	ECJ	could	not	
allow	Sterling	Drug	to	block	the	import	of	the	medicine	from	the	U.K.	to	Netherlands.	If	
it	did	so,	 it	would	cross	the	lines	of	free	movement	of	goods	 inside	the	E.E.A..94	As	 it	
can	 be	 concluded,	 the	 main	 criterion	 of	 whether	 parallel	 import	 is	 legal	 or	 illicit	 is	
whether	the	exhaustion	of	the	patent	right	has	occurred	in	the	E.E.A..95		
Although	to	some	it	may	seem	that	there	is	a	clash	between	competition	and	patents,	
the	 truth	 is	 that	patents,	 and	 generally	 intellectual	 property	 rights,	 promote	healthy	
competition	 and	 consumer’s	 welfare.	 Pharmaceutical	 patents	 are	 imperative,	 since	
they	 encourage	 research,	 innovation	 and	 investments.	 They	 also	 allow	 consumers	 –	
																																																						
93	(Jones	and	Sufrin,	2014),	pp.	853-854.	
94	(Σταματούδη,	2006),	pp.	64-65.	
95	(Χρυσάνθης,	2012),	p.	2.	
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patients	 to	 obtain	 information	 about	 the	 medicines	 and	 choose	 between	 them,	 of	
course	on	the	quota	that	they	are	free	to	choose.	To	create	a	strong	single	and	united	
European	market,	balance	is	needed	among	the	different	competing	interests.96		
THE	ASTRAZENECA	CASE	
One	probably	of	the	most	important	competition	law	pharmaceutical	cases	of	the	last	
decade	is	case	C-457/10	P,	AstraZeneca	A	and	AstraZeneca	plc	v.	European	Commission	
(2012).	The	AstraZeneca	case	is	a	positive	one	regarding	generics.	A	lot	of	articles	and	
books	were	written	for	this	case,	which	seems	to	affect	the	way	European	pharmaceu-
tical	industry	works.	
According	 to	 the	 ECJ,	 AstraZeneca	 has	 committed	 two	 abuses	 of	 dominance	 (Article	
102	TFEU)	of	 the	patent	system.	 It	has	made	“misleading	 representations”	of	certain	
dates	 to	national	patent	offices	 to	extent	 the	protection	granted	 to	one	of	 its	block-
buster	gastrointestinal	treatments	(“Losec”)	by	SPC.97	Moreover,	by	selective	deregis-
tration	of	 its	medicine’s	older	 form,	 it	has	not	allowed	pharmaceutical	 companies	 to	
obtain	 marketing	 authorization	 for	 their	 generics	 (Article	 4(3)(8)(a)(iii)	 Directive	
65/65).98	 AstraZeneca	 demanded	 the	 withdrawal	 of	 the	marketing	 authorizations	 in	
Denmark,	 Norway	 and	 Sweden.	 However,	 this	 action	 could	 result	 the	 restriction	 of	
parallel	import	of	the	products	to	these	countries.99	As	the	ECJ	stated,	a	dominant	un-
dertaking	 “has	 a	 special	 responsibility	 […]	 it	 cannot	 therefore	 use	 regulatory	 proce-
dures	 in	such	a	way	as	to	prevent	or	make	more	difficult	 the	entry	of	competitors	on	
the	market,	in	the	absence	of	grounds	relating	to	the	defense	of	the	legitimate	interests	
of	an	undertaking	engaged	in	competition	on	the	merits	or	in	the	absence	of	objective	
																																																						
96	(Goldberg	and	Lonbay,	2000),	p.	xiii.	
97	(Jones	and	Sufrin,	2014),	p.	558.	
98	(Mehta,	2012),	p.	1.	
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justification”.	Unfortunately,	this	approach	was	a	bit	narrow,	since	there	was	no	con-
sideration	regarding	the	case	where	equally	efficient	competitors	were	excluded.100	
AstraZeneca	case	has	many	consequences.	First,	there	is	a	lowering	of	the	grounds	for	
the	existence	of	an	abuse	of	dominance,	since	the	key	behind	it	the	intention	of	a	dom-
inant	 to	preclude	generics	from	entering	the	market.101	The	AstraZeneca	case	has	af-
fected	the	application	of	article	102	TFEU.102	Second,	this	case	showed	the	need	to	an-
alyze	 the	 pharmaceutical	 market	 and	 its	 complex	 structure.	 Last	 but	 not	 least,	 the	
competent	authorities	are	now	triggered	to	further	question	patent	procedures.103	
All	 these	consequences	are	of	equal	 importance,	but	 the	most	 important	one,	 in	my	
opinion,	is	the	first	one.	A	new	standard	was	created	as	regards	abuse	of	dominance,	a	
standard	that	is	about	to	change	the	way	pharmaceutical	market	works.	It	is	vital	that	
since	 the	grounds	 for	 accusing	a	 company	 for	 an	abuse	are	 lowered,	balance	 is	pre-
served.	This	must	not	be	used	thoughtlessly	by	companies	that	wish	to	promote	their	
rights.	The	main	positive	idea	that	should	be	concluded	by	this	case	is	that	generics	will	
no	longer	be	excluded	from	the	pharmaceutical	market	by	any	abuse	of	the	dominant	
companies.				
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THE	ISSUE	OF	“ACCESS	TO	MEDICINES”	
Two	main	issues	were	discussed	regarding	science,	legislation	and	case	law	of	pharma-
ceutical	 patents.	 The	 first	
one	concerns	the	legality	of	
their	 existence	 and	 the	 se-
cond	one	the	consequences	
of	 TRIPS	 Agreement.	 TRIPS	
Agreement	clearly	seems	to	
recognize	 the	 grant	 of	
pharmaceutical	 patents.104	 However,	 the	 mere	 existence	 of	 pharmaceutical	 patents	
seems	to	create	problems	regarding	access	to	medicines.		
THE	PROBLEM	
The	issue	of	“access	to	medicines”	is	a	complicated	one.	It	concerns	the	global	political	
economy	 and	 involves	many	 political,	 social,	 economical,	medical	 and	moral	 dimen-
sions	(Figure	9:	Pictures	used	by	WHO	for	access	to	medicines.).	Nowadays,	access	to	medicines	
is	becoming	a	priority	concern	both	for	developing	and	developed	countries.	The	high	
prices	 of	medicines	 and	 the	 exacerbation	of	 diseases,	 especially	 in	 developing	 coun-
tries,	make	it	impossible	for	some	patients	to	have	access	to	them.	Public	interests	are	
crucial	to	be	protected.105	Moreover,	TRIPS	Agreement	seems	to	help	the	rise	of	prices	
for	patented	medicines	and	to	make	access	to	medicines	more	difficult.106	
The	response	to	these	fears	was	the	adaptation	of	the	Doha	Declaration	in	2001.	Ac-
cording	 to	 the	Doha	Declaration,	 public	 health	was	 in	 priority	 position	 compared	 to	
																																																						
104	(Χρυσάνθης,	2012),	p.	699.	
105	(Gurgula,	2017),	p.	1.	
106	(Naik,	2006),	p.	48.	
Figure	9:	Pictures	used	by	WHO	for	access	to	medicines.	
Source:	(The	World	Health	Organization	(WHO),	2016)	
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pharmaceutical	patents	and	some	health	safeguards	were	put.	First,	it	was	emphasized	
that	TRIPS	Agreement	should	not	prevent	World	Trade	Organization	(WTO)	member	–	
States	from	protecting	healthcare	rights.	Second,	 it	was	stated	that	TRIPS	Agreement	
should	 be	 interpreted	 as	 an	 agreement	 that	 promotes	 access	 to	 medicines.	 Third,	
there	is	the	provision	of	compulsory	licensing	in	pharmaceuticals,	which	can	be	deter-
mined	in	details	by	each	member	–	State.	The	same	applies	also	for	parallel	import.107		
In	2008,	the	E.U.	Commission	begun	an	investigation	regarding	the	E.U.	pharmaceuti-
cal	industry.	Unfortunately,	the	result	was	not	good	enough,	since	most	pharmaceuti-
cal	companies	have	found	ways	to	extend	the	commercial	life	of	medicines	and	to	de-
lay	the	production	of	generics.108	According	to	the	WHO,	fair	access	to	safe	and	afford-
able	medicines	is	crucial	for	a	high-level	healthcare.	To	enhance	this,	WHO	member	–	
States	adopted,	in	2008,	a	resolution	on	“Global	strategy	and	plan	of	action	on	public	
health,	innovation	and	intellectual	property”.109	A	new	international	treaty	named	An-
ti-Counterfeiting	Trade	Agreement	(ACTA)	is	being	discussed	and	negotiating	between	
developed	countries	to	help	in	a	vital	manner	the	issue	of	access	to	medicines.110			
PHARMACEUTICAL	PATENTS	LICENSES	
Pharmaceutical	patent	licenses	enhance	not	only	access	to	medicines	but	also	the	fur-
ther	development	of	the	pharmaceutical	market.	 It	 is	considered	that	patent	acquisi-
tions	and	their	transfer	 is	promoting	competition.111	They	enhance	the	dissemination	
of	technology	and	innovation.112	Whether	a	pharmaceutical	company	is	an	ethical	one,	
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it	will	respect	the	pharmaceutical	patent	of	another	and	would	seek	for	the	grant	of	a	
license.113		
Pharmaceutical	 patent	 licenses	 are	 the	 solution	 given	 to	 a	manufacturer,	 when	 the	
pharmaceutical	 product	 that	 he/she	wishes	 to	 sell	 is	 protected	 by	 another’s	 patent.	
They	involve	the	grant	by	the	patent	owner	of	a	license	to	the	licensee	that	authorizes	
the	licensee	to	exploit	this	patent,	usually	in	return	for	the	payment	of	royalties.	114		
According	to	article	102	TFEU,	neither	dominance	nor	its	creation	and	preservation	is	
prohibited.	115		It	only	prohibits	its	abusive	use.116	There	are	cases	where	pharmaceuti-
cal	patent	owners	refused	to	license	third	parties	and	to	give	them	the	right	to	exploit	
these	rights.	This	refusal	is	abusive,	when	more	dominant	companies	seem	to	take	ad-
vantage	of	their	position	against	the	less	dominant	ones.	However,	for	this	provision	to	
be	used,	someone	must	first	prove	that	the	pharmaceutical	company	that	refused	to	
grant	 the	 license	 is	a	dominant	one	 in	 the	 relevant	product	and	geographic	pharma-
ceutical	market.		
It	appears	to	exist	some	tension	between	patents	and	competition	law,	since	the	first	
grants	exclusivity,	while	the	second	is	 in	favor	of	free	competition.	As	the	article	345	
TFEU	states,	«the	Treaties	shall	in	no	way	prejudice	the	rules	in	Member	–	States	gov-
erning	 the	system	of	property	ownership».117	Thus,	 the	EU	 legislation	and	article	102	
TFEU	are	not	able	to	annul	patents.	To	solve	this	problem,	the	EU	case	law	developed	
the	 doctrine	 of	 «dichotomy»	 of	 the	 existence	 and	 exercise	 of	 intellectual	 property	
rights.	This	doctrine	states	that	article	102	TFEU	is	not	allowed	to	affect	the	existence	
of	pharmaceutical	patents.	Only	 their	exercise	can	be	reviewed	by	 the	E.U.	Law.	The	
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list	in	article	102	TFEU	is	a	non-exhaustive	one.	«Abuse»	is	a	legal	term	that	needs	fur-
ther	interpretation.118	Article	102	TFEU	considers	that	an	abusive	refusal	to	license	can	
take	several	forms,	depending	on	the	circumstances	of	the	case.119	However,	a	refusal	
to	 license	must	be	taken	in	consideration	when	the	medicine	is	objectively	necessary	
and	when	the	refusal	could	harm	fair	competition	in	the	downstream	market	and	the	
patients	–	consumers.120		
However,	 pharmaceutical	 companies	 seem	 to	 find	 several	 ways,	 sometimes	 even	 a	
combination	of	them,	to	protect	their	medicines	against	generics.	A	typical	example	is	
the	Perindopril	 case	 (2014).	According	 to	 the	Commission,	Les	Laboratories	Servier,	a	
French	pharmaceutical	company,	has	started	an	anti-generics	strategy	 from	1990s.	 It	
protected	 its	most	 popular	medicine,	 “Perindopril”,	 by	patents	 and	 reverse	payment	
settlements.	 Servier’s	 patent	 practice	 was	 complicated	 and	 was	 consisted	 by	 many	
smaller	key	patents	that	covered	the	basic	one.	It	also	developed	a	filing	for	blocking	
patents	strategy.	The	Commission	found	that	these	acts	were	violating	E.U.	Competi-
tion	Law	and	especially	article	101	TFEU	and	article	102	TFEU	as	an	abuse	of	dominant	
position.121	Of	course,	it	is	essential	that	competition	authorities	first	take	into	consid-
eration	whether	 the	pharmaceutical	company	possesses	substantial	market	power	 in	
the	pharmaceutical	market	and	whether	these	acts	enhance	its	monopoly,	in	order	to	
claim	that	there	is	indeed	a	case	of	abuse	of	dominant	position.122	
Another	case	concerning	licenses	is	the	Genentech	Inc.	v.	Hoechst	GmbH	case.	Genen-
tech,	a	U.S.	pharmaceutical	company,	could	use	the	“HCMV	enhancer”	to	produce	pro-
teins	 for	 research	 purposes	 and	 for	 new	 products	 that	 would	 be	 sold	 in	 return	 for	
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agreed	loyalties,	according	to	the	license	agreement	that	it	has	signed	with	Hoechst,	a	
German	biotechnology	company.	The	 license	provided	by	 the	agreement	was	a	non-
exclusive	one.	Unfortunately,	Genentech	failed	to	pay	any	royalties	and	then	informed	
Sanofi	–	Aventis	(Hoechst’s	subsidiary	company)	its	wish	to	terminate	their	agreement.	
Hoechst	filed	for	the	settlement	of	dispute	via	arbitration	in	the	International	Court	of	
Arbitration	(ICC).	According	to	the	award,	Genentech	was	found	wrong	and	obligated	
to	 pay	 any	 royalties	 owned.	 On	 the	 other	 hand,	 Genentech’s	 opinion	 was	 that	 this	
award	was	a	violation	of	Article	101	TFEU.	The	ECJ	stated	that	Article	101	TFEU	should	
not	be	interpreted	in	way	that	it	precludes	the	payment	of	royalties	provided	by	a	li-
cense	agreement,	even	 if	 the	same	agreement	provides	the	right	to	terminate	the	 li-
cense	by	a	reasonable	notice.123	
COMPULSORY	LISENCING	
The	definition	provided	by	the	WTO	states	 that	compulsory	 licensing	 is	when	a	State	
“…allows	 someone	else	 to	produce	 the	patented	product	or	process	without	 the	con-
sent	of	 the	patent	owner”.	The	main	difference	that	occurred	after	Doha	Declaration	
was	that	there	was	also	a	provision	for	least	–	developed	countries	and	countries	that	
did	not	have	production	capacity.124	
Compulsory	licensing	in	pharmaceutical	does	not	annul	the	existence	of	a	pharmaceu-
tical	patent.	The	patent	owner	has	all	the	rights	that	exist	in	a	patent	and	also	the	right	
to	royalties	regarding	the	authorized	copies	of	the	pharmaceutical	products.	Generics	
that	are	produced	under	compulsory	licensing	are	mainly	for	the	domestic	market	and	
are	not	exported	to	other	countries,125	thus	neither	profit	nor	competition	for	pharma-
ceutical	companies	 is	harmed.	TRIPS	Agreement	does	not	enlist	 specific	 reasons	 that	
justify	compulsory	 licensing,	but	Doha	Declaration	allows	member	–	States	 to	decide	
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freely	about	 them.126	 	 In	E.U.	 compulsory	 licensing	 is	 still	unstable.	 Even	 though	 it	 is	
generally	agreed	that	compulsory	licensing	in	pharmaceuticals	should	exist	 in	“excep-
tional	circumstances”,	 these	circumstances	are	not	precisely	defined,	causing	 trouble	
in	the	interpretation	of	this	term.127	
However,	 TRIPS	 Agreement	 (article	 31)	 enlists	 conditions	 that	 define	 compulsory	 li-
censing.	First,	 that	the	one	interested	in	applying	for	compulsory	 license	should	have	
already	 tried	 to	negotiate	a	 voluntary	 license,	but	 in	 vain.	Although,	 if	 there	 is	 a	na-
tional	 emergency	 or	 an	 extreme	 urgency,	 the	 scale	 of	 the	 voluntary	 license	 can	 be	
skipped.	Second,	a	compulsory	license	does	not	eliminate	the	need	of	payment	of	roy-
alties	to	the	patent	owner.	Of	course,	compulsory	license	is	a	non-exclusive	one,	since	
the	 patent	 owner	 can	 continue	 the	 production	 of	 the	 medicine.128	 	 In	 my	 opinion,	
compulsory	licensing	is	a	crucial	step	taken	towards	the	elimination	of	the	problem	of	
access	to	medicines	that	can	be	caused	due	to	pharmaceutical	patents.	
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Conclusions	
It	is	concluded	by	the	definitions	given	that	medicine	is	not	a	simple	term.	It	is	only	log-
ical	that	the	industry	that	deals	with	medicines	is	also	a	complicated	one.	Pharmaceu-
tical	industry’s	structure	is	multidimensional	and	hides	many	conflicting	rights.	To	bal-
ance	 the	situation,	 the	existence	of	pharmaceutical	patents	 is	 crucial.	However,	 they	
must	not	be	used	thoughtlessly.		
Between	 the	different	 types	of	medicines,	 the	one	 that	 causes	 the	more	disputes	 in	
the	pharmaceutical	industry	is	the	generic	one.	Generics	enhance	competition	and	are	
the	solution	to	the	problem	of	access	to	medicines,	however	the	one-sided	promotion	
of	 them	will	 destroy	 the	whole	pharmaceutical	market.	 Investors	will	 no	 longer	 give	
funds	 to	 innovative	 research	 and	 archetype	 companies	will	 be	 financially	 destroyed.	
Pharmaceutical	 patents	 are	 imperative	 in	 this	 industry	 to	 protect	 the	 prototypes’	
rights.	There	 is	an	obvious	 interaction	between	pharmaceutical	patents	and	generics.	
The	end	of	a	patent	is	to	be	considered	the	beginning	of	a	generic.	If	patents	did	not	
exist,	generics	would	not	exist	either.	The	lack	of	patent	protection	would	cause	a	cha-
otic	situation,	since	there	would	be	no	distinction	between	an	archetype	medicine	and	
a	generic	one.		
On	the	one	hand,	pharmaceutical	patents	ensure	a	 legal	monopoly	 in	 the	market,	as	
regards	the	prototypes	pharmaceutical	companies,	as	a	form	of	reward	for	their	inno-
vation	and	as	motivation	for	further	and	unstoppable	high	(in	quality	and	quantity)	in-
vestment	in	the	pharmaceutical	market	and	technology.	The	costs	of	the	production	of	
new	medicines	are	sky-high	and	companies	need	to	make	profit	to	continue	their	good	
work.	As	it	is	used	in	every	market,	in	the	pharmaceutical	industry	profit	plays	a	crucial	
role	for	funds	to	be	released	on	research	of	new	medicines.	However,	in	pharmaceuti-
cal	industry,	the	common	feeling	of	health	and	human	life	enhances	more	the	innova-
tion	in	research.	
On	the	other	hand,	healthy	competition	must	not	be	forgotten	in	the	pharmaceutical	
market	and	can	be	succeeded	by	the	promotion	of	generics.	Pharmaceutical	market	is	
a	complicated	market	and	it	is	imperative	that	its	structure	is	further	analyzed	my	leg-
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islators	to	create	new	and	more	efficient	legislation	that	can	both	control	pharmaceu-
tical	 patents,	 without	 depriving	 pharmaceutical	 companies’	 rights,	 and	 promote	 a	
healthy	competition	and	thus	satisfied	patient	–	consumers.	Pharmaceutical	market’s	
share	is	really	huge	to	be	divided	only	by	few	companies.	It	could	be	divided	by	more	
companies	that	can	equally	offer	to	healthcare	and	promote	humanity’s	quality	life.		
It	 seems,	however,	 that	 the	whole	basis	of	pharmaceutical	market	should	change.	 In	
the	pharmaceutical	market	the	patient	–	consumer	is	not	the	one	who	takes	the	deci-
sion	concerning	the	medicines	and	demand	is	estimated	by	other	factors.	In	my	opin-
ion,	this	is	the	reason	why	healthcare	deals	with	so	many	problems	and	why	pharma-
ceutical	industry’s	structure	should	be	first	mapped	and	then	improved.	
The	AstraZeneca	decision	has	created	a	new	standard	as	regards	abuse	of	dominance,	
a	 standard	 that	could	change	 the	way	pharmaceutical	market	works.	But	even	 if	 the	
grounds	of	accusing	a	company	for	an	abuse	are	lowered	by	this	ECJ	decision,	balance	
should	be	preserved.	This	decision	must	not	be	used	thoughtlessly	by	generics	compa-
nies	 that	wish	 to	 promote	 their	 rights.	 The	main	 positive	 conclusion	 that	 should	 be	
kept	is	that	generics	will	no	longer	be	excluded	from	the	pharmaceutical	market	by	any	
abuse	of	the	dominant	companies	regarding	pharmaceutical	patents.	It	seems	like	the	
limit	needed	to	safeguard	both	sides	was	finally	given	by	the	ECJ.				
These	 facts	 are	 really	 important	 and	 so	 every	 state	 needs	 to	 follow	 a	well-balanced	
strategy	that	can	promote	them.	If	balance	is	not	kept,	healthcare	will	be	hugely	hurt	
and	disease	and	even	death	rates	may	rise,	especially	 in	developing	countries	where	
access	to	medicines	is	still	under	construction.	Health	is	the	most	important	gift	given	
to	a	person	and	should	be	well	preserved.	Thus,	medicines,	which	actually	exist	to	cure	
people,	 should	 not	 be	 unreachable	 for	 them.	 However,	 since	 their	 manufacture	 re-
quires	 immense	amount	of	both	money	and	 time,	pharmaceutical	 companies	 should	
be	encouraged	to	continue	research	by	the	safeguard	of	patent	law.			
In	my	opinion,	 the	 reason	behind	 the	 existence	of	 pharmaceutical	 patents	 is	 indeed	
the	promotion	of	 innovation	and	fair	and	healthy	competition.	Even	though	numbers	
seem	to	show	that	pharmaceutical	companies	earn	great	amount	of	money	due	to	pa-
tents	and	the	monopoly	that	they	create,	it	is	not	to	be	forgotten	that	they	also	spent	
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enormous	amounts	 in	 research	and	 innovation.	Pharmaceutical	patents	 interact	with	
the	pharmaceutical	 industry.	The	extinction	of	the	one	would	cause	the	extinction	of	
the	other	with	the	form	that	is	known.		
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